Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855589 | 0.94 | CYP19A1 (0.45) | CYP19A1MITFLMNACNR1CNR2 | |
| SCHEMBL6963246 | 0.91 | SERPINH1 (0.39) | CYP19A1MITFLMNACNR1CNR2 | |
| SCHEMBL66024 | 0.88 | SCN5A (0.44) | CYP19A1MITFLMNACNR1CNR2 | |
| SCHEMBL66945 | 0.86 | SCN5A (0.43) | CYP19A1MITFLMNACNR1CNR2 | |
| SCHEMBL6963985 | 0.85 | HSPB1 (0.46) | CYP19A1LMNACNR1CNR2HTT | |
| SCHEMBL7235718 | 0.80 | HRH1 (0.50) | LMNACNR1CNR2GPR55HTT | |
| SCHEMBL26106019 | 0.80 | IDO1 (0.32) | LMNAHTTMEN1KMT2A | |
| SCHEMBL5586175 | 0.80 | IDO1 (0.32) | LMNAHTTMEN1KMT2A | |
| SCHEMBL13619654 | 0.80 | AOC3 (0.44) | LMNANPSR1MEN1KMT2A | |
| SCHEMBL27999842 | 0.80 | HTT (0.37) | LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771175-B1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-12 | — | — | US | disclosed |
| US-8946221-B2 | Phthalazine derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-02-03 | — | — | US | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | MEVELLEC LAURENCE ANNE | 2011-03-17 | — | — | US | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1771175-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006003147-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1059922-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044596-A2 | GLYCINE TRANSPORT INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-10 | — | — | WO | disclosed |
| EP-0151826-B1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| US-4839374-A | TREATING ALLERGIES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1989-06-13 | — | — | US | disclosed |
| US-4695575-A | ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | CYP19A1 486/4885MITF 1931/4885LMNA 274/4885 |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CYP19A1 1083/4885MITF 2687/4885LMNA 598/4885 |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | CYP19A1 486/4885MITF 1931/4885LMNA 274/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CYP19A1 1083/4885MITF 2687/4885LMNA 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.